Other

Debt and Equity Securities, Cost

Vertex Pharmaceuticals Debt and Equity Securities, Cost increased by 4.2% to $7.50B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 12.2%, from $6.69B to $7.50B. Over 5 years (FY 2020 to FY 2025), Debt and Equity Securities, Cost shows an upward trend with a 68.8% CAGR.

Analysis

StatementBalance Sheet Statement
SectionOther
First reportedQ2 2018
Last reportedQ1 2026
Metric ID: other_debtand_equity_securities_cost

Historical Data

20 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$541.59M$535.84M$568.90M$554.90M$553.00M$584.90M$374.40M$2.18B$2.48B$2.57B$3.36B$5.44B$5.67B$5.96B$6.68B$6.69B$7.05B$7.04B$7.20B$7.50B
QoQ Change—-1.1%+6.2%-2.5%-0.3%+5.8%-36.0%+483.2%+13.5%+3.6%+30.9%+61.8%+4.3%+5.2%+12.0%+0.2%+5.3%-0.1%+2.3%+4.2%
YoY Change————+2.1%+9.2%-34.2%+293.5%+348.1%+339.0%+797.6%+149.0%+128.8%+132.2%+98.8%+23.1%+24.3%+18.1%+7.8%+12.2%
Range$374.40M – $7.50B
CAGR+73.9%
Avg YoY Growth+146.8%
Median YoY Growth+61.6%
Current Streak2 quarters growth

Frequently Asked Questions

What is Vertex Pharmaceuticals's debt and equity securities, cost?
Vertex Pharmaceuticals (VRTX) reported debt and equity securities, cost of $7.50B in Q1 2026.
How has Vertex Pharmaceuticals's debt and equity securities, cost changed year-over-year?
Vertex Pharmaceuticals's debt and equity securities, cost increased by 12.2% year-over-year, from $6.69B to $7.50B.
What is the long-term trend for Vertex Pharmaceuticals's debt and equity securities, cost?
Over 5 years (2020 to 2025), Vertex Pharmaceuticals's debt and equity securities, cost has grown at a 68.8% compound annual growth rate (CAGR), from $526.02M to $7.20B.